According to a recent joint announcement by the U.S. Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIH), the seventh wave of data files for the Population Assessment of Tobacco and Health (PATH) study's biomarker data (BRUF) has been released. This marks the first release of biomarker data collected between January 2022 and April 2023.
According to the official website of the FDA, the PATH (Population Assessment of Tobacco and Health) study is a large-scale, long-term research project on tobacco use and health in the United States. This study is conducted in collaboration with the FDA's Center for Tobacco Products and the National Institute on Drug Abuse Research, began in 2011, and commenced the first round of data collection in 2013.
The primary goal of this study is to help scientists understand the ways and reasons people start smoking, quit smoking, and then start again after quitting by tracking research subjects over the long term. It also aims to investigate the effects of different tobacco products on health, such as cardiovascular and respiratory health. Additionally, the research results may serve as a reference for the FDA to develop actions related to tobacco products, ultimately helping to achieve the goals set out in the Family Smoking Prevention and Tobacco Control Act.
According to the FDA website, researchers can now apply to access these restricted use biological marker data files (BRUF). In addition, the first round of data files has been updated to include samples from adults who have previously experimented with or used any tobacco products. The main linked files for restricted and public use have also been updated to reflect the new files and the current availability of samples in the biological sample acquisition program.
The following is the web address for the seventh wave of biomarker data files on the FDA website:
The provided link leads to the summary of a study available on the ICPSR website.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
